Which stock wins in a matchup between a top cannabis retailer and the leading marijuana REIT?
Two mid-cap biotechs. Two tremendously successful drugs already on the market. But which is the better long-term stock pick?
Disappointing fourth-quarter results are taking a toll on the medical device stock.
There are two possible answers. And neither one of them is good.
The CyberKnife maker missed Wall Street bottom-line estimates and announced disappointing guidance for fiscal 2020.
Investors appear to be worried that the company's growth could be stymied by the FDA's sluggishness in establishing CBD regulations.
The cannabis producer's stunning revenue decline and massive net loss in Q1 have investors worried.
Piper Jaffray likes several U.S. cannabis stocks and one Canadian pot stock better than Aurora. Here are the analyst's picks -- and why they're good ones.
The Canadian cannabis producer's latest results were much worse than anyone expected.
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
The cannabidiol (CBD) leader returned to solid sequential revenue growth, but its spending soared even more than its sales did.
The Canadian cannabis producer looks for even stronger growth in the future thanks to its increased production capacity and entrance into new markets.
Shares of this CBD pioneer are falling as a result of Q2 revenue and earnings misses.
Disappointing Q2 results are causing some investors to bail on the Canadian cannabis producer.
Put more fizz in your portfolio with these solid dividend stocks.
They're flying high right now. But are these three healthcare stocks smart picks?
These cannabis stocks boast sizzling sales growth. But are they great picks for investors to buy now?
There wasn't much to like with the molecular diagnostics company's latest quarterly update.
Revenue soared, but there's more to the story with the Canadian cannabis producer's second-quarter update.
Who cares about lower produce sales when the company's cannabis joint venture is booming?